How do you work in decentralized trials?

The way clinical research operates is changing significantly, moving away from the mandatory, repeated visits to a central site towards models that integrate more directly into participants' daily lives. This shift defines what we call decentralized clinical trials, or DCTs, where research activities are brought closer to where patients live and work, often by incorporating remote technologies and services. ^[1][4] Fundamentally, it is about reducing the burden on participants by minimizing or eliminating the need to travel to specific physical locations for every protocol requirement. ^[8]

A decentralized trial isn't necessarily an all-or-nothing proposition; it exists on a spectrum. ^[2] Some studies are fully remote, relying entirely on virtual interactions and direct-to-patient supplies, while many others adopt a hybrid approach. ^[1][7] In a hybrid model, certain essential procedures might still require an in-person visit—perhaps for an initial informed consent, a specialized imaging procedure, or a safety check—but routine follow-ups, data collection, and assessments are managed remotely. ^[1][4] This flexibility is key to modernizing trial design, often overlapping with concepts like pragmatic clinical trials which focus on effectiveness in real-world settings. ^[2]

# Defining Components

To function, a decentralized trial must integrate several core elements that replace or supplement traditional site functions. ^[5][7] Think of these components as the building blocks that shift activity from the site office to the patient's home or local community. ^[8]

First, remote data capture is paramount. This involves using electronic patient-reported outcomes (ePROs) or electronic clinical outcome assessments (eCOAs) administered via mobile devices or wearables to collect subjective and objective data directly from the participant. ^[7] This captures data in real-time rather than relying on retrospective patient recall during a scheduled clinic visit. ^[1]

Second, telehealth or direct virtual communication is essential for remote monitoring and regular check-ins. ^[5] Investigators and study coordinators can conduct remote visits, review safety data, and provide study updates without the patient needing to travel. ^[1] This also often involves remote study monitoring, where monitors can review source documentation electronically, reducing the need for frequent on-site monitoring visits. ^[6]

Third, direct-to-patient (DtP) services handle the physical aspects that cannot be done remotely. ^[5] This includes shipping investigational product (IP) directly to the participant's home or another convenient location. ^[4] It also covers the coordination of local services, such as having home health nurses conduct specific procedures like phlebotomy or administering injections locally, rather than requiring travel to the main study site. ^[5][8]

A critical enabling factor, which often gets overlooked when describing the visible components, is the underlying technology infrastructure. It’s not enough to have several separate apps for ePRO, eConsent, and telehealth; the true work happens when these systems can securely communicate and feed data into the central electronic data capture (EDC) system. ^[10] If the technology stack lacks strong integration, the decentralized trial simply becomes a collection of disconnected digital tasks, increasing the administrative load rather than reducing the patient burden. A well-executed DCT demands standardized data exchange protocols to ensure data integrity across all remote touchpoints. ^[9]

# Operational Shift

Working within a decentralized structure fundamentally alters day-to-day responsibilities for site staff, sponsors, and participants alike. ^[3][5]

For the participant, the experience is centered on convenience. They might receive a pre-packaged kit containing necessary devices, instructions, and, if needed, supplies for home health visits. ^[8] Their primary engagement is often through a study app or a secure web portal. ^[7]

For the site staff—the coordinators and investigators—the primary change is in how they manage their workload and interact with participants. Instead of focusing heavily on managing physical visits and handling paper documents, their work shifts toward:

1. Remote Coordination: Managing incoming data streams from wearables and ePROs daily, rather than waiting for a scheduled visit to review data. ^[9]
2. Technology Support: Acting as the first line of technical support for participants struggling with apps, device setup, or data submission. ^[9]
3. Local Logistics: Coordinating with third-party vendors, such as DtP pharmacies or home health agencies, to ensure services are delivered on time and according to the protocol. ^[10]

This operational pivot means that successful site personnel need skillsets extending beyond traditional clinical research management; they need aptitude in remote communication, troubleshooting digital tools, and managing complex vendor relationships. ^[5] An additional nuance arises in managing source documentation. While remote monitoring reduces site burden, sites must still maintain accurate, auditable records. In a decentralized setting, this often means ensuring that all electronic records generated from remote devices or remote staff accurately map back to the official study record, which requires clear standard operating procedures (SOPs) for digital archiving. ^[6]

How do you work in fair work platforms?

# Benefits Realized

The driving force behind adopting decentralized elements is the ability to overcome traditional barriers to trial participation. ^[8]

One of the most significant advantages is enhanced participant recruitment and retention. ^[4] By removing geographical barriers, studies can access larger and more diverse patient populations who might otherwise be excluded due to distance, lack of transport, or inflexible work schedules. ^[8] This increased accessibility can dramatically shorten recruitment timelines. ^[4] Furthermore, reducing the burden of travel often leads to better adherence to the protocol, as participants are less likely to drop out due to logistical fatigue. ^[1][4]

Another clear gain is higher quality, more frequent data. ^[1] When assessments are done using wearables or continuous diaries in the participant’s real-world environment, the data gathered often reflects daily life more accurately than data collected sporadically during a clinic visit. ^[7] This proximity to the actual experience can provide richer insights into both efficacy and tolerability. ^[8]

From a logistical standpoint, sponsors can sometimes see reduced site overhead. ^[3] While new technology costs are involved, reducing the required physical space, dedicated equipment, and high volume of on-site staff for routine tasks can offer cost efficiencies over the long term. ^[4]

# Planning and Governance

Implementing a decentralized study requires careful forethought, often starting much earlier in the study planning phase than traditional trials. ^[10] The CTTI emphasizes that planning for decentralized elements should begin during the protocol development stage to ensure all necessary logistical and technological requirements are embedded from the start. ^[10]

A successful plan must explicitly address which activities will be decentralized and how they will be executed and verified. ^[2] Sponsors and sites need to clearly define the technology stack and vet vendors thoroughly. ^[9] This vetting process should focus not just on the technology's features but also on its security compliance, ease of use for diverse populations, and its ability to integrate with the primary trial database. ^[7]

Regulatory compliance remains a central consideration. Regulatory bodies, such as the FDA, have issued guidance supporting the use of decentralized elements, provided the protection of human subjects and the integrity of the resulting data are maintained. ^[6] Investigators remain responsible for participant safety regardless of where the assessment takes place. ^[6] Therefore, clear communication protocols between remote healthcare providers (like the home nurse) and the principal investigator are mandatory for timely safety reporting. ^[9]

If a study involves participants using personal devices (Bring Your Own Device or BYOD), the protocol must detail the processes for ensuring data security and compliance, especially when incorporating local healthcare providers who may not be familiar with clinical trial documentation standards. ^[2][6]

How do you work in mission-driven innovation?

# Practical Application Tips

Navigating the actual execution requires a focus on clarity and support for everyone involved.

One immediate, practical step involves simplifying the participant interface. ^[9] Since participants are using technology often outside a controlled clinic setting, instructions must be exceptionally clear, perhaps utilizing video tutorials embedded directly within the app or requiring a dedicated, scheduled tech check-in call before the first use of a complex device. ^[5] If the technology is confusing or difficult to access, the benefits of decentralization disappear quickly, leading to data gaps and participant frustration.

Another crucial element for smooth operation involves defining the local support network explicitly. If a home health nurse needs to perform a blood draw, the study team must pre-establish the chain of custody for that sample, including the specific temperature requirements for transport back to a central lab or local testing facility. ^[10] This coordination requires dedicated staff time to manage vendor schedules, confirm sample integrity documentation, and troubleshoot inevitable delays that occur outside the controlled environment of a research site. ^[9] Considering local context is also important; for instance, relying on high-speed home internet might be standard in one geographic area but completely impractical in another, necessitating alternative data transmission methods or reliance on site-based backup visits. ^[8]

Finally, sponsors must treat the technological backbone like a core component of the drug supply chain, not an afterthought. Establishing standardized integration methods between all third-party tech vendors (eWOM, wearables, DtP logistics) and the central EDC system upfront prevents massive data reconciliation efforts late in the trial. ^[10] If the systems don't talk directly, the sponsor must allocate significant resources—personnel and time—to manually merge or map these disparate data sets, negating some of the efficiency gains. ^[3] The success of the decentralized model hinges on the data flowing continuously and accurately without constant manual intervention.